Proactive Investors - Run By Investors For Investors

Kazia Therapeutics developing unique drug to battle brain cancer

Kazia Therapeutics Limited (NASDAQ:KZIA)(ASX:KZA) CEO James Garner sat down with Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

The Sydney, Australia based oncology-focused biotechnology company develops anti-cancer drugs; its pipeline includes two clinical-stage drug development candidates. Its lead candidate is GDC-0084, which has entered a phase II clinical trial in March 2018, with initial data expected in early calendar 2019.

Meet Cardinal Resources Ltd, Legend Mining Ltd, Danakali Ltd, Predictive Discovery Ltd and Alliance Resources Ltd at our event, Melbourne , 16 July 2019. Register here »
View full KZA profile View Profile

Kazia Therapeutics Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use